Results 91 to 100 of about 98,415 (200)

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Trials
Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or ...
Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux   +9 more
doaj   +1 more source

High temperature and humidity in the environment disrupt bile acid metabolism, the gut microbiome, and GLP-1 secretion in mice

Communications Biology
High temperature and humidity in the environment are known to be associated with discomfort and disease, yet the underlying mechanisms remain unclear.
Song Chen, Zongren Hu, Jianbang Tang, Haipeng Zhu, Yuhua Zheng, Jiedong Xiao, Youhua Xu, Yao Wang, Yi Luo, Xiaoying Mo, Yalan Wu, Jianwen Guo, Yongliang Zhang, Huanhuan Luo   +13 more
doaj   +1 more source

Once-weekly glucagon-like peptide 1 receptor agonists.

JPMA. The Journal of the Pakistan Medical Association, 2015
The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Signaling architecture of the glucagon-like peptide-1 receptor. [PDF]

J Clin Invest
Austin G, Tomas A.
europepmc   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Interactions of a Glucagon-like peptide 1 and a Glucagon-like peptide 1 analogue, liraglutide, with the endogenous receptor [PDF]

, 2015
Bukrinski, Jens T., Frederiksen, Tine Maja, Harris, Pernille, Peters, Günther H.J.   +3 more
core  

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology. [PDF]

Acta Physiol (Oxf)
Ruiz MA, Furquim THDC, Davaanyam D, Williams NR, Polotsky VY, Amorim MR.   +5 more
europepmc   +1 more source